451 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving Atezolizumab

451 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving Atezolizumab

Bibliographic Details
Main Authors:	Kai Sun, Maen Abdelrahim, Yuqi Zhang, Catherine Wiechmann, Jiaqiong Xu, Ethan Burns, Ryan Kieser, Shivan Shah, Godsfavour Umoru, Abdullah Esmail, Kelly Gee
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

1233 Impact of infections occurring in patients receiving immune checkpoint inhibitors for renal cell carcinoma (RCC)
by: Jun Zhang, et al.
Published: (2023-11-01)

1234 Impact of infections in patients receiving immune checkpoint inhibitor therapies for non-small cell lung cancer (NSCLC)
by: Jun Zhang, et al.
Published: (2023-11-01)

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer
by: Ethan A. Burns, et al.
Published: (2022-12-01)

Case report: Efficacy and safety of regorafenib plus fluorouracil combination therapy in the treatment of refractory metastatic colorectal cancer
by: Emaan Haque, et al.
Published: (2022-12-01)

Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report
by: Maen Abdelrahim, et al.
Published: (2022-06-01)

Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
by: Yuwa Ando, et al.
Published: (2022-11-01)

Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
by: Alessandro Rizzo, et al.
Published: (2021-12-01)

Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab
by: Yun Beom Sang, et al.
Published: (2024-02-01)

Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
by: Supachaya Sriphoosanaphan, et al.
Published: (2024-01-01)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
by: Naoto Saito, et al.
Published: (2022-07-01)

Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
by: Takahiro Kinami, et al.
Published: (2024-03-01)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
by: Shigeki Yano, et al.
Published: (2023-11-01)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
by: Ryosuke Tsunemitsu, et al.
Published: (2023-06-01)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
by: Loïg Gaugain, et al.
Published: (2023-01-01)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
by: Hideki Iwamoto, et al.
Published: (2021-06-01)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
by: Hannah Yang, et al.
Published: (2023-04-01)

Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma
by: Hiroaki Matsumoto, et al.
Published: (2022-07-01)

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
by: Yuwa Ando, et al.
Published: (2021-08-01)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
by: Yue Linda Wu, et al.
Published: (2022-11-01)

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma
by: Zijian Yang, et al.
Published: (2023-01-01)

Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma
by: Yasuhito Mitsuyama, MD, et al.
Published: (2023-09-01)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
by: Tetsu Tomonari, et al.
Published: (2023-02-01)

Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients– multicenter analysis
by: Atsushi Hiraoka, et al.
Published: (2022-12-01)

Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
by: Mohamed Badheeb, et al.
Published: (2022-11-01)

Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma
by: Alexander Villalobos, et al.
Published: (2023-11-01)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Toshifumi Tada, et al.
Published: (2023-04-01)

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
by: Chung‐Wei Su, et al.
Published: (2023-03-01)

Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysisResearch in context
by: Anand V. Kulkarni, et al.
Published: (2023-09-01)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
by: Zhao C, et al.
Published: (2023-07-01)

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab
by: Kei Endo, et al.
Published: (2022-08-01)

The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
by: Awiwi MO, et al.
Published: (2022-08-01)

Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma
by: Tasuku Nakabori, et al.
Published: (2024-03-01)

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
by: Beom Kyung Kim, et al.
Published: (2022-03-01)

Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma
by: Chien-Yu Tseng, et al.
Published: (2023-11-01)

Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study
by: Chanchai Charonpongsuntorn, et al.
Published: (2022-12-01)

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab
by: Yasuto Takeuchi, et al.
Published: (2023-09-01)

Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study
by: Machiko Kai, et al.
Published: (2024-01-01)

Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study
by: Ji Hoon Kim, et al.
Published: (2023-08-01)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
by: Young Eun Chon, et al.
Published: (2023-02-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)